Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Inhoudelijk Toledo Draadje
Volgen
A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects.clinicaltrials.gov/ct2/history/NCT046...
Lama Daila schreef op 13 februari 2021 10:31 :
clinicaltrials.gov/ct2/history/NCT045... LADYBUG (GLPG3970 in RA) is al volledig gerecruteerd.
Study completion is met een maand vervroegd: van mei naar april
28 patiënten ipv 25
Deze studie zou toch al "completed" moeten zijn?
www.clinicaltrials.gov/ct2/show/NCT04... Studie met 3970 in UC is nu ook lopende. Active!
clinicaltrials.gov/ct2/history/NCT047... TAPINOMA studie (GLPG3970 in SLE): 3 nieuwe locaties in Polen.
Tijd voor wat educatie :) TAPINOMA wordt ook wel “draaigatje” genoemdnl.wikipedia.org/wiki/Mediterraan_dra... De benaming draaigatje komt van de door de mier toegepaste manier van verdedigen: eerst bijten en dan het achterlijf naar de wond draaien en er een irriterende stof in spuiten.
Rigorous new review of SIKs biology and therapeutic potential for diseaseses.Nuts and bolts of the salt-inducible kinases (SIKs)
Het patent voor GLPG3970 (2e Toledo patent) is op 21/04 gepubliceerd.patentscope.wipo.int/search/en/detail... patentscope.wipo.int/search/docs2/wip... Provisional protection under Article 67:www.epo.org/law-practice/legal-texts/... Protectie tot 2019 + 20 = 2039
Gilead Sciences (GILD) Q1 2021 Earnings Call Transcript GILD earnings call for the period ending March 31, 2021. Galapagos SIK2/3 Toledo proof-of-concept trials across psoriasis, ulcerative colitis, and RA are expected to have readouts later this year.Our next question comes from Matthew Harrison with Morgan Stanley. Matthew Harrison -- Morgan Stanley -- Analyst Great. Good afternoon. Thanks for taking the question. A question on Galapagos, and I guess there are two parts here. First part is, you know, you've got these upcoming Toledo readouts. Merdad, maybe you could just comment on what you're potentially looking to see from those readouts, given that the duration of those trials is fairly short. So maybe what you would view as sort of a positive outcome. And then I guess second question is a more sort of broader strategic question here.But if you don't see something that's positive out of those, you know, how do you think about the longer-term relationship there? And given that you're the largest shareholder, you know, what might you consider in terms of that relationship? Merdad Parsey -- Chief Medical Officer Yes, sure. It's a great question. And I think you -- Matthew, you mentioned, I think, look, where we are now with the Toledo programs is looking for evidence of tolerability and proof-of-concept, proof of principle for that pathway in multiple indications. And I would describe these early small studies as a place to demonstrate that and look to see where the biggest impact could be. I think it's an early part of the longer journey, ranging from -- you know, is there a particular indication that we want to pursue further to confirm and expand on the signal to -- you know, do we have the right molecule for that. So I think we view these, together with Galapagos, I believe, we view these as sort of very early in the story of the Toledo program. So we'll be looking to see what those data look like in the near term. Dan, do you want add?Daniel O'Day -- Chairman and Chief Executive Officer Sure. So maybe just to you, Matthew, to just give a little bit of context of people that may not be completely familiar with our relationship with Galapagos. So of course, there was the filgotinib relationship, but then there was a separate relationship that we went into. As you know, a couple of years ago now. And that was really based on the research platform . And I would say that nothing has really changed in relation to that. I mean one of the reasons to do that was to diversify our approaches from a discovery research perspective across, if you like, the Gilead Group. I listened hard to the scientists at that time. I continue to listen hard to the scientists today. They think they have a very discriminated platform for screening compounds for first-in-class . And I'll remind you, that's really the approach first-in-class, which, of course, comes with some risks, some of which we've seen in the later-stage programs. And of course, Toledo is the most advanced now of those programs. But having said that, there are many others within their discovery platform that we continue to be intrigued about. I think it's an important part of our overall inflammation strategy, albeit at an earlier stage for Gilead. But when we think about our strategic approach that really focuses on immunology and virology as our core scientific skills, we have now obviously leaders in virology built up a really significant presence in oncology with inflammatory disorders, really kind of the next step and the next stage of our platform where Galapagos presents, I think one aspect of that, but a very important aspect in terms of first-in-class approach. So we continue to be working very closely with our partners at Galapagos to determine what the next screens are and what the next targets are in the concept of our -- the entirety of our inflammation strategy. So thanks, Matt.Inflammatory Diseases Pipeline (Pipeline shown below as of end of Q121)
Wall Street Trader schreef op 20 februari 2021 17:41 :
Thanks to pate
Salt-inducible kinases are required for the IL-33-dependent secretion of cytokines and chemokines in mast cells16 February 2021
Interestingly, the biotechnology company Galapagos disclosed on October 27th 2020 that compounds from their “Toledo” programme, target the SIK family of protein kinases and that a dual SIK2/SIK3 inhibitor
GLPG3970 had passed Phase I trials and would soon be entering advanced clinical trials for Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis.
The present study, which shows that the combined inhibition of SIK2/3 suppresses the production of a number of cytokines and chemokines that contribute to the pathogenesis of asthma now suggests that GLPG3970 and/or related compounds may be worth exploring as potential treatments for asthma patients who are refractory to the corticosteroid therapies that are in widespread use.
www.sciencedirect.com/science/article... Zelfde artikel (in meer leesbare layout) van University of Dundee:discovery.dundee.ac.uk/ws/portalfiles... “Our results suggest that dual inhibitors of SIK2 and SIK3 may have therapeutic potential for the treatment of mast cell–driven diseases.” GLPG3970 zou dus mogelijk ook wel eens kunnen werken tegen asthma, of andere mast cell-driven diseases.
Lama Daila schreef op 26 maart 2021 07:36 :
[...]
In de webcast van Piet met Morgan Stanley verduidelijkt Pïet dat GLPG4876 een backup is voor GLPG3970 en dat er momenteel weinig of geen plannen zijn met GLPG4876
morganstanley.webcasts.com/viewer/eve... Q1 2021: We selected an additional molecule from our Toledo program, SIK2/3 inhibitor ‘4876, as a candidate to accelerate from preclinical phase into clinical development; Backup voor GLPG3970 die uit de schuif gehaald wordt??
Q1 2021: We completed enrollment of the SEA TURTLE Phase 2 study with ‘3970 in UC
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (LADYBUG )Recruitment Status : Completed First Posted : October 8, 2020 Last Update Posted : May 10, 2021clinicaltrials.gov/ct2/show/NCT04577781
Wall Street Trader schreef op 10 mei 2021 21:27 :
A Study Evaluating the Effects of
GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (
LADYBUG )
Recruitment Status : Completed First Posted : October 8, 2020
Last Update Posted : May 10, 2021
clinicaltrials.gov/ct2/show/NCT04577781 De data zijn dus bekend hopelijk snel geëvalueerd gezien de kleine aantal deelnemers.
Kleine nieuwe Toledo study met GLPG3970:clinicaltrials.gov/ct2/show/NCT04907149 Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970 6 personen, Completion date Juni 21 A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Metabolism of GLPG3970 in Healthy Male Subjects Following a Single Oral Dose of GLPG3970 Relative to an Intravenous [14C]GLPG3970 Microtracer and Single Oral [14C]GLPG3970 Administration Drug: GLPG3970 film-coated tablet Participants will receive a single oral dose of GLPG3970. Drug: [14C]GLPG3970 solution for infusion Participants will receive an i.v. microtracer microdose.
Wall Street Trader schreef op 10 mei 2021 21:27 :
A Study Evaluating the Effects of
GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (
LADYBUG )
Recruitment Status : Completed First Posted : October 8, 2020
Last Update Posted : May 10, 2021
clinicaltrials.gov/ct2/show/NCT04577781 Hoe zit het eigenlijk met het onderzoek in UC : had toch ook al completed moeten zijn?????
abelheira schreef op 20 juni 2021 21:12 :
[...]
Hoe zit het eigenlijk met het onderzoek in UC : had toch ook al completed moeten zijn?????
zie iets hoger 6 mei dus
MtBaker schreef op 21 juni 2021 08:44 :
[...]zie iets hoger 6 mei dus
Enrollment is completed maar onderzoek zou ook al completed moeten zijn.
abelheira schreef op 21 juni 2021 09:59 :
[...]
Enrollment is completed maar onderzoek zou ook al completed moeten zijn.
Op 4 mei al een publicatie over fase 3 in The Lancet verschenen.
Down the drain 2 schreef op 21 juni 2021 10:05 :
[...]
Op 4 mei al een publicatie over fase 3 in The Lancet verschenen.
Het gaat over Toledo, niet over de Ph 3 studie met Filgotinib in UC. Die is in The Lancet verschenen laatst. De 3970 studie in UC was mid april 'completed enrollment' --> Active, not recruiting dus. Wil zeggen 6 weken extra + 2 weken follow up --> mid juni completed studie. Tenminste indien de timings op clinical trials kloppen wat niet altijd het geval is. Vaak worden die ook pas een maand later bijgewerkt (zie eerdere studies met 3970, 3667 en Filgotinib). Studie is dus completed nu, maar moet nog aangepast worden op clinical trials, in juli zouden de eerste drie POC's hiervan uitlezen.
Down the drain 2 schreef op 21 juni 2021 10:05 :
[...]
Op 4 mei al een publicatie over fase 3 in The Lancet verschenen.
Je weet ook echt niet waar het over gaat, of wel?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)